tiprankstipranks
Trending News
More News >
Vivos Therapeutics (VVOS)
NASDAQ:VVOS
US Market
Advertisement

Vivos Therapeutics (VVOS) AI Stock Analysis

Compare
217 Followers

Top Page

VVOS

Vivos Therapeutics

(NASDAQ:VVOS)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - 4o)
Rating:44Neutral
Price Target:
$2.50
▼(-6.37% Downside)
Vivos Therapeutics faces significant financial and operational challenges, with negative profitability and cash flow issues being the most impactful factors. Technical analysis indicates bearish momentum, and valuation metrics are weak. Despite strategic initiatives and financing, the current outlook remains cautious.
Positive Factors
Strategic Acquisition
The acquisition of The Sleep Center of Nevada provides Vivos with direct access to a large patient base, enhancing revenue potential and aligning with the company's strategic pivot towards high patient volume centers.
Revenue Growth Potential
The deployment of Sleep Optimization Teams is expected to significantly boost revenue with high contribution margins, supporting long-term growth and profitability.
Financing Secured
Securing significant financing provides Vivos with the necessary capital to support strategic acquisitions and future growth initiatives, enhancing financial stability.
Negative Factors
Revenue Decline
A decline in revenue indicates challenges in maintaining sales momentum, which could impact the company's ability to achieve profitability and sustain growth.
Increased Operating Loss
Rising operating losses due to increased expenses from acquisitions and lower revenues can strain financial resources, affecting long-term financial health.
High Leverage Risks
High leverage poses risks to financial stability, potentially limiting the company's ability to invest in growth opportunities and manage economic downturns.

Vivos Therapeutics (VVOS) vs. SPDR S&P 500 ETF (SPY)

Vivos Therapeutics Business Overview & Revenue Model

Company DescriptionVivos Therapeutics, Inc. (VVOS) is a medical device company focused on the development and commercialization of innovative solutions for the treatment of sleep-disordered breathing, particularly obstructive sleep apnea (OSA). The company operates in the healthcare sector, offering a range of products that utilize advanced technology to provide non-invasive therapies aimed at improving the quality of life for patients suffering from sleep-related issues. Vivos Therapeutics is known for its proprietary oral appliance therapy, which aims to address the underlying anatomical causes of sleep apnea rather than just its symptoms.
How the Company Makes MoneyVivos Therapeutics generates revenue primarily through the sale of its patented medical devices and treatment systems for sleep apnea. The company operates a direct-to-consumer model as well as a business-to-business model, partnering with dental and healthcare professionals to promote and distribute its products. Key revenue streams include the sale of its oral appliances, ongoing treatment subscriptions, and potential licensing agreements. Vivos also benefits from collaborations with healthcare providers and institutions that utilize its technology in patient care, contributing to recurring revenue through follow-up treatments and related services.

Vivos Therapeutics Earnings Call Summary

Earnings Call Date:Aug 19, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 12, 2025
Earnings Call Sentiment Neutral
The earnings call reflects a period of transition for Vivos Therapeutics, with significant investments and strategic changes aimed at long-term growth through the SCN acquisition and deployment of SO teams. While the company has secured financing and reports early success with SCN, current financial performance has been negatively impacted by decreased revenue and increased operating losses.
Q2-2025 Updates
Positive Updates
SCN Acquisition and Integration
Vivos Therapeutics completed the acquisition of the Sleep Center of Nevada (SCN) on June 10, 2025. The acquisition contributed $500,000 in sleep testing service revenue within just 20 days of closing. The company is encouraged by the cooperation and buy-in from the SCN medical team.
Deployment of Sleep Optimization Teams
Vivos has deployed 1.5 new sleep optimization (SO) teams and plans to expand to 4.5 teams across two SCN locations by the end of 2025. Each SO team is expected to generate over $500,000 in monthly net collections with contribution margins above 50%.
Significant Financing Secured
The company secured $11.5 million in net cash from financing activities, supported by an affiliate of Seneca Partners, to fund the SCN acquisition and support future growth.
Negative Updates
Revenue Decline
Revenue decreased by 6% to $3.8 million in Q2 2025 compared to $4.1 million in Q2 2024. The overall revenue for 2025 decreased by 9% due to a $1.7 million drop in VIP enrollment revenue.
Increased Operating Loss
Operating loss widened to $4.9 million in Q2 2025 and $8.8 million for 2025 due to higher expenses from the SCN acquisition and lower revenues during the strategic transition.
Increased Costs
Cost of sales and operating expenses increased significantly, primarily due to the acquisition and integration of SCN, with $1.8 million in associated costs.
Company Guidance
In the second quarter of 2025, Vivos Therapeutics, Inc. experienced a 6% revenue decline to $3.8 million compared to the same period in 2024, partially due to the strategic pivot from their VIP enrollment model, which saw a $1.7 million drop. However, the company reported a $500,000 increase in sleep testing service revenue post-acquisition of the Sleep Center of Nevada (SCN) on June 10, 2025, which also contributed an additional $500,000 uplift in sponsorship, seminar, and other service revenue. The acquisition led to a significant rise in costs, including $1.8 million in expenses related to SCN integration and operating expenses, pushing the operating loss to $4.9 million for the quarter. Despite these challenges, the company secured $11.5 million in net cash from financing activities, including equity financing from Seneca Partners, and anticipates future revenue growth through the deployment of Sleep Optimization Teams (SO teams) and additional acquisitions. Vivos Therapeutics remains optimistic about the strategic transition and expects cash flow positivity in the fourth quarter of 2025 as they continue expanding their operations and facilities.

Vivos Therapeutics Financial Statement Overview

Summary
Vivos Therapeutics shows revenue growth but struggles with profitability and cash flow. The balance sheet indicates improved equity but high leverage risks. Overall, financial stability and sustainable growth remain challenges.
Income Statement
45
Neutral
Vivos Therapeutics has shown some positive revenue growth, with a 8.9% increase in 2024 compared to 2023. However, the company continues to face challenges in achieving profitability, indicated by negative EBIT and EBITDA margins, and a net income of zero in 2024. The consistent negative net profit margin over the years highlights ongoing operational struggles.
Balance Sheet
55
Neutral
The balance sheet reflects improving equity, with stockholders' equity rising to $7.95 million in 2024 from $0.41 million in 2023, suggesting strengthened financial stability. However, the debt-to-equity ratio is relatively high, indicating potential leverage risks. The equity ratio remains moderate, demonstrating a balanced asset structure, but further stability is needed.
Cash Flow
40
Negative
The cash flow statement reveals persistent negative free cash flow, with minimal improvement over the years. Operating cash flow remains negative, highlighting ongoing cash burn, although financing activities have supported liquidity. The company needs to focus on improving operational efficiency to enhance cash flow stability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue14.39M15.03M13.80M16.02M16.89M13.07M
Gross Profit8.05M9.02M8.27M10.02M12.60M10.41M
EBITDA-13.43M-10.55M-16.68M-24.36M-19.54M-11.24M
Net Income-14.32M-11.14M-13.58M-23.84M-20.29M-12.06M
Balance Sheet
Total Assets26.03M15.28M10.73M13.72M33.69M25.33M
Cash, Cash Equivalents and Short-Term Investments4.40M6.26M1.64M3.52M24.03M18.21M
Total Debt11.58M1.51M2.00M2.41M1.63M1.29M
Total Liabilities21.45M7.33M10.32M8.92M8.15M8.41M
Stockholders Equity4.58M7.95M411.00K4.80M25.54M16.92M
Cash Flow
Free Cash Flow-15.14M-13.26M-12.75M-20.51M-18.13M-5.80M
Operating Cash Flow-14.42M-12.69M-11.95M-19.59M-15.73M-5.68M
Investing Cash Flow-6.38M-568.00K-853.00K-924.00K-2.61M-120.25K
Financing Cash Flow18.30M17.88M10.92M0.0024.17M23.54M

Vivos Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.67
Price Trends
50DMA
3.65
Negative
100DMA
3.90
Negative
200DMA
3.61
Negative
Market Momentum
MACD
-0.23
Positive
RSI
27.01
Positive
STOCH
15.39
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VVOS, the sentiment is Negative. The current price of 2.67 is below the 20-day moving average (MA) of 3.08, below the 50-day MA of 3.65, and below the 200-day MA of 3.61, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 27.01 is Positive, neither overbought nor oversold. The STOCH value of 15.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VVOS.

Vivos Therapeutics Risk Analysis

Vivos Therapeutics disclosed 85 risk factors in its most recent earnings report. Vivos Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Vivos Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
45
Neutral
$17.67M-105.72%0.09%51.09%
44
Neutral
$21.76M-262.03%2.65%70.21%
44
Neutral
$16.65M-63.40%-91.14%9.47%
41
Neutral
$22.30M15.00%71.57%
40
Underperform
$24.05M-26.49%-91.23%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VVOS
Vivos Therapeutics
2.67
0.03
1.14%
IRIX
Iridex
1.06
-0.48
-31.17%
CODX
Co-Diagnostics
0.32
-0.92
-74.19%
ADGM
Adagio Medical Holdings
1.34
-1.36
-50.37%
COCH
Envoy Medical
0.80
-1.77
-68.87%
NXL
Nexalin Technology, Inc.
1.51
0.15
11.03%

Vivos Therapeutics Corporate Events

Vivos Therapeutics’ Earnings Call: Strategic Transition and Growth
Sep 1, 2025

Vivos Therapeutics Navigates Transition with Strategic Investments

Vivos Therapeutics Shifts Strategy Amid Financial Challenges
Aug 20, 2025

Vivos Therapeutics, Inc. is a medical technology company specializing in proprietary oral appliances and therapeutic treatments for sleep disorders, particularly obstructive sleep apnea (OSA). The company operates in the healthcare sector and is known for its innovative, non-surgical solutions for maxillofacial abnormalities linked to breathing and sleep issues.

Vivos Therapeutics Delays Q2 2025 10-Q Filing
Aug 14, 2025

Vivos Therapeutics, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The delay is primarily due to the recent acquisition of The Sleep Center of Nevada, which requires additional time for auditing and integration of financial statements. The company expects to file the report within the five-day extension period allowed by the SEC. Financially, Vivos anticipates a significant increase in general and administrative expenses, leading to a material rise in net loss for the quarter compared to the previous year, largely due to one-time acquisition costs. The company remains committed to compliance, with CFO Bradford Amman signing off on the notification.

The most recent analyst rating on (VVOS) stock is a Buy with a $6.60 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 23, 2025